COMPARISON OF ULTRASONOGRAPHIC FINDINGS WITH CLINICAL ACTIVITY INDEX (CIBDAI) AND DIAGNOSIS IN DOGS WITH CHRONIC ENTEROPATHIES

2008 ◽  
Vol 49 (1) ◽  
pp. 56-64 ◽  
Author(s):  
LORRIE GASCHEN ◽  
PATRICK KIRCHER ◽  
ANJA STÜSSI ◽  
KARIN ALLENSPACH ◽  
FRÉDÉRIC GASCHEN ◽  
...  
Keyword(s):  
Activity Index ◽  
Clinical Activity ◽  
Chronic Enteropathies

Effect of Saccharomyces boulardii in dogs with chronic enteropathies: double-blinded, placebo-controlled study

2017 ◽  
Vol 182 (9) ◽  
pp. 258-258 ◽  
Author(s):  
Simona D’Angelo ◽  
Federico Fracassi ◽  
Francesca Bresciani ◽  
Roberta Galuppi ◽  
Alessia Diana ◽  
...  
Keyword(s):  
Body Condition Score ◽  
Activity Index ◽  
Clinical Signs ◽  
Saccharomyces Boulardii ◽  
Controlled Study ◽  
Clinical Activity ◽  
Short Term ◽  
Chronic Enteropathies ◽  
Healthy Dogs ◽  
Double Blinded

Saccharomyces boulardii is used to treat acute and chronic enteropathies in humans, but to date, no studies have evaluated the use of this yeast in dogs. The current study, a prospective non-randomised, double-blinded, placebo-controlled study, evaluated the effects of S boulardii in healthy dogs and dogs with chronic enteropathies (CE). Four healthy dogs and 20 dogs with CE were included. In healthy dogs, S boulardii was administered for 10 days. Possible short-term adverse effects were recorded, and quantitative stool cultures for yeasts were performed. In dogs with CE, S boulardii or a placebo was administered in addition to standard treatment protocols. Canine Chronic Enteropathy Clinical Activity Index, abdominal ultrasonography, gastroenteroscopy and histology were performed at the time of diagnosis and after 60 days of treatment. In healthy dogs, S boulardii reached a steady state in five days and was completely eliminated on day 4 after administration. No short-term side effects were seen. Clinical activity index, stool frequency, stool consistency and body condition score improved significantly in dogs with CE receiving S boulardii versus the placebo. In conclusion, S boulardii can be safely used in dogs with CE and seems to achieve better control of clinical signs than standard therapy alone.

scholarly journals The Impact of Chronic Inflammatory Enteropathy on Dogs’ Quality of Life and Dog-Owner Relationship

2021 ◽  
Vol 8 (8) ◽  
pp. 166
Author(s):  
Veronica Marchetti ◽  
Eleonora Gori ◽  
Valeria Mariotti ◽  
Angelo Gazzano ◽  
Chiara Mariti
Keyword(s):  
Quality Of Life ◽  
Negative Impact ◽  
Activity Index ◽  
Control Group ◽  
Clinical Activity ◽  
Chronic Enteropathies ◽  
Healthy Dogs ◽  
The Impact

This research was aimed at evaluating the impact of canine chronic enteropathies on dogs’ quality of life (QoL), their behavior, and owner–dog relationship. Forty-four dogs suffering from primary chronic enteropathies were assessed on the first visit with a veterinary gastroenterologist and on the first follow-up visit using a 1–10 visual scale to evaluate five features of QoL, the Canine Chronic Enteropathy Clinical Activity Index, the Lexington Attachment to Pet Scale, and the Canine Behavioral Assessment and Research Questionnaire. They were compared to a control group of 49 healthy dogs and to a group of 50 dogs suffering from cancer. QoL and severity of enteropathy were negatively associated; enteropathic dogs on the first visit had a lower QoL than healthy dogs for all features and a lower general QoL than cancer patients; enteropathic dogs on the follow-up visit improved significantly for general QoL, health QoL, and interaction QoL. Higher levels of attachment between the owner and the dog were obtained for dogs affected by chronic enteropathies. Finally, dogs showed higher scores for separation-related behaviors and contact/attention behaviors on the first visit than on the subsequent follow-up. As in human medicine, chronic enteropathies have a strong negative impact on dogs.

Vasoactive intestinal peptide as a laboratory supplement to clinical activity index in inflammatory bowel disease

1989 ◽  
Vol 34 (10) ◽  
pp. 1528-1535 ◽  
Author(s):  
Linda C. Duffy ◽  
Maria A. Zielezny ◽  
Marie Riepenhoff-Talty ◽  
Tim E. Byers ◽  
James Marshall ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Vasoactive Intestinal Peptide ◽  
Bowel Disease ◽  
Activity Index ◽  
Clinical Activity ◽  
Inflammatory Bowel

scholarly journals P187 The significance of netrin-1 level in the clinical activity of ulcerative colitis, its association between TNF-α and IL-6

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S232-S232
Author(s):  
H Korkmaz ◽  
K Fidan
Keyword(s):  
Ulcerative Colitis ◽  
Proinflammatory Cytokines ◽  
Activity Index ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Clinical Activity ◽  
Tnf Α ◽  
Significant Difference ◽  
And Control ◽  
Control Study

Abstract Background In this study, we investigated the importance of netrin-1 levels in ulcerative colitis (UC) in clinical activity of the disease, and its association with other proinflammatory cytokines IL-6 and TNF-α. Methods This study is a type of case–control study. Sixty-seven patients with UC (36 of them activation, 31 of remission) and 50 healthy controls were included in the study. UC patients; ‘Truelove Witts clinical activity index by remission (n = 31), mild activation (n = 21), moderate activation (n = 6) and severe activation (n = 9) were divided into groups. Netrin, IL-6 and TNF-α measurements in plasma samples were performed using enzyme-linked immunosorbent assay kit. Results Between the patient group and the control group; there was a statistically significant difference between netrin-1, IL-6, TNF-α, neutrophil, platelet (p < 0.05 for all). The plasma netrin-1 mean of UC with severe activation group (139.21 ± 48.09 pg/ml) was statistically significantly higher than that of the mild activation (p = 0,037), remission group (p = 0,001) and control group(p = 0,011). The plasma netrin-1 mean of UC with moderate activation group was statistically significantly higher than that of the mild activation(p = 0,045) and remission group(p = 0,004). Conclusion Our results reveal that plasma netrin-1 levels have been shown to be associated with UC activation, similar to proinflammatory cytokines such as TNF-α and IL-6, in UC.

scholarly journals Correlating Gastrointestinal Histopathologic Changes to Clinical Disease Activity in Dogs With Idiopathic Inflammatory Bowel Disease

2018 ◽  
Vol 56 (3) ◽  
pp. 435-443 ◽  
Author(s):  
Karin A. Allenspach ◽  
Jonathan P. Mochel ◽  
Yingzhou Du ◽  
Simon L. Priestnall ◽  
Frances Moore ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Disease Activity ◽  
Bowel Disease ◽  
Scoring System ◽  
Activity Index ◽  
Clinical Disease ◽  
Clinical Activity ◽  
Clinical Disease Activity ◽  
Inflammatory Bowel ◽  
Histopathologic Changes

Prior studies have failed to detect a convincing association between histologic lesions of inflammation and clinical activity in dogs with inflammatory bowel disease (IBD). We hypothesized that use of a simplified histopathologic scoring system would improve the consistency of interpretation among pathologists when describing histologic lesions of gastrointestinal inflammation. Our aim was to evaluate the correlation of histopathologic changes to clinical activity in dogs with IBD using this new system. Forty-two dogs with IBD and 19 healthy control dogs were enrolled in this retrospective study. Endoscopic biopsies from the stomach, duodenum, ileum, and colon were independently scored by 8 pathologists. Clinical disease activity was scored using the Canine Inflammatory Bowel Disease Activity Index (CIBDAI) or the Canine Chronic Enteropathy Clinical Activity Index (CCECAI), depending on the individual study center. Summative histopathological scores and clinical activity were calculated for each tissue (stomach, duodenum, ileum, and colon) and each tissue histologic score (inflammatory/morphologic feature). The correlation between CCECAI/CIBDAI and summative histopathologic score was significant ( P < .05) for duodenum ( r = 0.42) and colon ( r = 0.33). In evaluating the relationship between histopathologic scores and clinical activity, significant ( P < .05) correlations were observed for crypt dilation ( r = 0.42), lamina propria (LP) lymphocytes ( r = 0.40), LP neutrophils ( r = 0.45), mucosal fibrosis ( r = 0.47), lacteal dilation ( r = 0.39), and villus stunting ( r = 0.43). Compared to earlier grading schemes, the simplified scoring system shows improved utility in correlating histopathologic features (both summative histology scores and select histologic scores) to IBD clinical activity.

scholarly journals Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease

Gut ◽  
1999 ◽  
Vol 44 (5) ◽  
pp. 625-628 ◽  
Author(s):  
M F Neurath ◽  
R Wanitschke ◽  
M Peters ◽  
F Krummenauer ◽  
K-H Meyer zum Büschenfelde ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Mycophenolate Mofetil ◽  
Side Effects ◽  
Crohn's Disease ◽  
Disease Activity ◽  
Activity Index ◽  
Randomised Trial ◽  
Chronic Inflammatory Disease ◽  
Clinical Activity ◽  
Small Subset

BACKGROUNDCrohn’s disease is a chronic inflammatory disease of the alimentary tract. Azathioprine is an effective agent in the management of chronic active Crohn’s disease leading to long term remission of disease activity. Such treatment leads to limited efficacy or side effects in a small subset of patients.AIMSTo compare efficacy and side effects of treatment with azathioprine plus corticosteroids versus mycophenolate mofetil (MMF) plus corticosteroids in patients with chronic active Crohn’s disease.METHODSSeventy patients with chronic active Crohn’s disease (Crohn’s disease activity index (CDAI) greater than 150) were randomised for treatment with azathioprine/cortisone or MMF/cortisone. Corticosteroid dosage was tapered according to a standard protocol. Disease activity was monitored by clinical scores after one, two, three, and six months.RESULTSTreatment of patients with moderately active (CDAI 150–300) Crohn’s disease with MMF/cortisone led to a significant reduction in clinical activity scores comparable to treatment with azathioprine/cortisone. Treatment of patients with highly active Crohn’s disease (CDAI greater than 300) with MMF/cortisone caused significant suppression of clinical activity earlier than azathioprine/cortisone treatment. Treatment with MMF/cortisone was associated with few adverse effects.CONCLUSIONTreatment of chronic active Crohn’s disease with MMF plus cortisone appears to be effective and well tolerated and should be considered in patients allergic to azathioprine or in whom azathioprine has failed.

Acute Pancreatitis Clinical Activity Index (AP-CAI) at Discharge Predicts Readmission for Acute Pancreatitis: 2016 ACG Lawlor Resident Award

2016 ◽  
Vol 111 ◽  
pp. S1 ◽  
Author(s):  
Michael Quezada ◽  
Ben Da ◽  
Bechien U. Wu ◽  
Chung Yao Yu ◽  
Ara Sahakian ◽  
...  
Keyword(s):  
Acute Pancreatitis ◽  
Activity Index ◽  
Clinical Activity

Treatment of inflammatory bowel disease (IBD) in dogs and cats

2011 ◽  
Vol 14 (1) ◽  
pp. 165-171 ◽  
Author(s):  
K. Malewska ◽  
A. Rychlik ◽  
R. Nieradka ◽  
M. Kander
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Symptoms ◽  
Activity Index ◽  
Disease Activity Index ◽  
Immunosuppressive Drugs ◽  
Clinical Activity ◽  
Aminosalicylic Acid ◽  
Probiotic Treatment ◽  
Inflammatory Bowel

Treatment of inflammatory bowel disease (IBD) in dogs and catsThe treatment of inflammatory bowel disease (IBD) possesses numerous difficulties owing to the unclear etiology of the disease. This article overviews the drugs used in the treatment of IBD depending on the intensity of clinical symptoms (Canine Inflammatory Bowel Disease Activity Index and Canine Chronic Enterophaty Clinical Activity Index). Patients demonstrating mild symptoms of the disease are usually placed on an appropriate diet which may be combined with immunomodulative or probiotic treatment. In moderate progression of IBD, 5-aminosalicylic acid (mesalazine or olsalazine) derivatives may be administered. Patients showing severe symptoms of the disease are usually treated with immunosuppressive drugs, antibiotics and elimination diet. Since the immune system plays an important role in the pathogenesis of the disease, the advancements in biological therapy research will contribute to the progress in the treatment of canine and feline IBD in the coming years.

Sign in / Sign up

Export Citation Format

Share Document